Background The role of secondary cytomegalovirus (CMV) prophylaxis, defined as the
continuation of valganciclovir to prevent relapse after the successful treatment of CMV …

Background Cytomegalovirus (CMV) remains the leading viral cause of disease following
orthotopic liver transplantation (OLT) despite the availability of antiviral agents for …

Liver transplantation recipients (LTRs) who are seropositive for cytomegalovirus
(CMV)(recipient seropositive [R+]) are at intermediate risk for CMV disease. A preventative …

Background Cytomegalovirus (CMV) is a major contributor to morbidity and mortality in solid
organ transplant recipients (SOTRs). Ganciclovir and valganciclovir are highly effective …

Background: Low-dose valganciclovir (VGC) for cytomegalovirus (CMV) prophylaxis post-
transplant has been employed due to cost and safety. The incidence of CMV disease in …

BACKGROUND: With the introduction of prolonged prophylaxis with valganciclovir in
cytomegalovirus (CMV) donor/recipient serodiscordance (D+/R−) patients, concerns about a …

CMV prevention strategies in liver transplant recipients should be stratified according to
serological status. In donor (D)-/recipient (R)-combinations, no prophylaxis or preemptive …

Valganciclovir (VGC) was approved by the Food and Drug Administration in 2004 as
cytomegalovirus (CMV) prophylaxis except for liver transplant recipients because of their …

Optimal measures for the prevention of cytomegalovirus (CMV) in high‐risk orthotopic liver
transplant (OLT) patients are unknown. The charts of high‐risk OLT recipients with 12 …

Background. Despite advances in antiviral therapies, cytomegalovirus (CMV) remains the
leading opportunistic infection in the transplant population. Valganciclovir (VGC), the l‐valyl …